IRA favors biologics over small molecule drugs and hurts innovation, industry analysts say
Roche is ‘on par’ with Novo, Lilly in GLP-1 race after $2.7B Carmot deal
Amgen emerges as potential Cytokinetics suitor as Novartis pulls away
Study finds hundreds of overlooked cancer drug targets
